Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.
Neurology News Network for the week ending July 2, 2022. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 1, 2022.
The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]
In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]
Jean Hubble, MD, semi-retired neurologist and consultant, spoke with the PMD Alliance at the ATMRD Congress about the advances made in the field and her hopes for the future of therapeutics and clinical care.
The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 3 minutes]
The BTK inhibitor is currently the subject of several ongoing phase 3 clinical trials that include more than 2000 patients currently on the therapy.
Despite not reaching the primary end point, the oromucosal spray is still being evaluated in 2 ongoing trials that comprise of 446 and 190 patients, respectively, with spasticity due to multiple sclerosis.
The chair of Cleveland Clinic’s Department of Physical Medicine provided insight on a newly approved modality aimed to improve rehabilitation efforts for patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Patients with high levels of neurofilament light at baseline had an increased risk of developing new T2 lesions and of experiencing a new clinical relapse in the follow-up period, but not of EDSS progression.
The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.
Following positive phase 2a findings, NeuroSense’s agent PrimeC continued to show a mechanistic impact on biomarkers specific to patients with amyotrophic lateral sclerosis.
The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]
Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed a recent study on a new tool aimed at quantifying movements during stroke rehabilitation.
Over a 12-week treatment period, brexpiprazole demonstrated statistically significant improvements on the primary and secondary end points compared with placebo.
Among a large cohort of outpatient and inpatient individuals, the risk of Alzheimer disease, Parkinson disease, ischemic stroke, and intracerebral hemorrhage were all elevated after infection, with stroke risk increased compared with other respiratory infections.
Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Jun Li, MD, PhD, of Houston Methodist Hospital. [WATCH TIME: 3 minutes]
Ocrelizumab (Ocrevus; Genentech), an anti-CD20 treatment FDA-approved for progressive MS, was shown to reduce thalamic volume loss, with even greater outcomes when initiated earlier.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone provided commentary on when the PrimSeq digital tool could see substantial impact on rehabilitation for stroke survivors and other neurological diseases. [WATCH TIME: 4 minutes]
During months 36 and 48 on open-label cenobamate treatment, 76.4% and 51.8% of patients achieved seizure reductions of at least 50% or 75%, respectively.
The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).
In total, 100% and 93% of those in the SMN two- and three-copy cohorts achieved the primary end point of sitting independently for at least 30 seconds after 18 months of treatment.
As the individualized needs of patients are further prioritized in Parkinson disease care, the director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute shared her perspective on shared decision-making. [WATCH TIME: 4 minutes]
Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.
The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]
Here's what is coming soon to NeurologyLive®.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed the current methods of prescribing rehabilitation and why a new digital tool can improve them going forward. [WATCH TIME: 3 minutes]
